Biotech News

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Heron Therapeutics (HRTX)Heron TherapeuticsEarnings

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.

Related news

Heron Therapeutics

Acute-Care Medicines Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care. Its portfolio is designed for administration in hospitals, ambulatory surgery centers and infusion settings. ZYNRELEF ZYNRELEF is an extended-release local anesthetic combining bupivacaine and meloxicam for...

Recent company news

Stock data

Close
0.26 USD
Market cap
85.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States